
Following a series of unimpressive quarters, Danish pharmaceutical company Novo Nordisk's obesity business is expanding again.
The industry has great expectations for this leg of the business, but so far, it only contains the treatment Saxenda which grew 9 percent in local currency over the course of Q1 to generate sales worth just over DKK 1.5bn (USD 242m).
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app